TMO vs. VTRS: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at TMO and VTRS, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | TMO | VTRS |
|---|---|---|
| Company Name | Thermo Fisher Scientific Inc. | Viatris Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Life Sciences Tools & Services | Pharmaceuticals |
| Market Capitalization | 185.31 billion USD | 12.30 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | March 17, 1980 | March 17, 1980 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of TMO and VTRS by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | TMO | VTRS |
|---|---|---|
| 5-Day Price Return | -1.51% | -1.22% |
| 13-Week Price Return | 22.54% | 24.12% |
| 26-Week Price Return | -7.56% | -3.48% |
| 52-Week Price Return | -18.73% | -9.83% |
| Month-to-Date Return | 4.93% | 20.71% |
| Year-to-Date Return | -5.67% | -15.26% |
| 10-Day Avg. Volume | 1.99M | 8.78M |
| 3-Month Avg. Volume | 2.75M | 12.06M |
| 3-Month Volatility | 33.71% | 31.14% |
| Beta | 0.78 | 0.91 |
Profitability
Return on Equity (TTM)
TMO
13.27%
Life Sciences Tools & Services Industry
- Max
- 19.96%
- Q3
- 11.55%
- Median
- 6.22%
- Q1
- 3.86%
- Min
- -6.95%
In the upper quartile for the Life Sciences Tools & Services industry, TMO’s Return on Equity of 13.27% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
VTRS
-19.92%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
VTRS has a negative Return on Equity of -19.92%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.
Net Profit Margin (TTM)
TMO
15.23%
Life Sciences Tools & Services Industry
- Max
- 27.28%
- Q3
- 16.17%
- Median
- 7.24%
- Q1
- 3.00%
- Min
- -3.05%
TMO’s Net Profit Margin of 15.23% is aligned with the median group of its peers in the Life Sciences Tools & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.
VTRS
-24.57%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
VTRS has a negative Net Profit Margin of -24.57%, indicating the company is operating at a net loss as its expenses exceeded its revenues.
Operating Profit Margin (TTM)
TMO
17.13%
Life Sciences Tools & Services Industry
- Max
- 33.15%
- Q3
- 19.34%
- Median
- 13.02%
- Q1
- 8.05%
- Min
- -4.38%
TMO’s Operating Profit Margin of 17.13% is around the midpoint for the Life Sciences Tools & Services industry, indicating that its efficiency in managing core business operations is typical for the sector.
VTRS
-26.54%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
VTRS has a negative Operating Profit Margin of -26.54%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.
Profitability at a Glance
| Symbol | TMO | VTRS |
|---|---|---|
| Return on Equity (TTM) | 13.27% | -19.92% |
| Return on Assets (TTM) | 6.62% | -8.50% |
| Net Profit Margin (TTM) | 15.23% | -24.57% |
| Operating Profit Margin (TTM) | 17.13% | -26.54% |
| Gross Profit Margin (TTM) | 41.34% | 40.15% |
Financial Strength
Current Ratio (MRQ)
TMO
1.93
Life Sciences Tools & Services Industry
- Max
- 4.76
- Q3
- 2.77
- Median
- 1.85
- Q1
- 1.40
- Min
- 0.43
TMO’s Current Ratio of 1.93 aligns with the median group of the Life Sciences Tools & Services industry, indicating that its short-term liquidity is in line with its sector peers.
VTRS
1.37
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
VTRS’s Current Ratio of 1.37 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
TMO
0.70
Life Sciences Tools & Services Industry
- Max
- 1.75
- Q3
- 0.83
- Median
- 0.41
- Q1
- 0.18
- Min
- 0.00
TMO’s Debt-to-Equity Ratio of 0.70 is typical for the Life Sciences Tools & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
VTRS
0.82
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
VTRS’s Debt-to-Equity Ratio of 0.82 is typical for the Pharmaceuticals industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
Interest Coverage Ratio (TTM)
TMO
23.55
Life Sciences Tools & Services Industry
- Max
- 29.61
- Q3
- 23.24
- Median
- 6.07
- Q1
- 2.18
- Min
- -14.08
TMO’s Interest Coverage Ratio of 23.55 is in the upper quartile for the Life Sciences Tools & Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
VTRS
-0.13
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
VTRS has a negative Interest Coverage Ratio of -0.13. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | TMO | VTRS |
|---|---|---|
| Current Ratio (MRQ) | 1.93 | 1.37 |
| Quick Ratio (MRQ) | 1.50 | 0.65 |
| Debt-to-Equity Ratio (MRQ) | 0.70 | 0.82 |
| Interest Coverage Ratio (TTM) | 23.55 | -0.13 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
TMO
0.33%
Life Sciences Tools & Services Industry
- Max
- 1.80%
- Q3
- 0.78%
- Median
- 0.37%
- Q1
- 0.00%
- Min
- 0.00%
TMO’s Dividend Yield of 0.33% is consistent with its peers in the Life Sciences Tools & Services industry, providing a dividend return that is standard for its sector.
VTRS
4.58%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
With a Dividend Yield of 4.58%, VTRS offers a more attractive income stream than most of its peers in the Pharmaceuticals industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio (TTM)
TMO
9.27%
Life Sciences Tools & Services Industry
- Max
- 156.00%
- Q3
- 65.73%
- Median
- 23.81%
- Q1
- 0.00%
- Min
- 0.00%
TMO’s Dividend Payout Ratio of 9.27% is within the typical range for the Life Sciences Tools & Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
VTRS
137.04%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
VTRS’s Dividend Payout Ratio of 137.04% is in the upper quartile for the Pharmaceuticals industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
Dividend at a Glance
| Symbol | TMO | VTRS |
|---|---|---|
| Dividend Yield (TTM) | 0.33% | 4.58% |
| Dividend Payout Ratio (TTM) | 9.27% | 137.04% |
Valuation
Price-to-Earnings Ratio (TTM)
TMO
28.41
Life Sciences Tools & Services Industry
- Max
- 117.96
- Q3
- 65.59
- Median
- 37.26
- Q1
- 27.51
- Min
- 1.73
TMO’s P/E Ratio of 28.41 is within the middle range for the Life Sciences Tools & Services industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
VTRS
--
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
P/E Ratio data for VTRS is currently unavailable.
Price-to-Sales Ratio (TTM)
TMO
4.33
Life Sciences Tools & Services Industry
- Max
- 12.46
- Q3
- 6.70
- Median
- 4.24
- Q1
- 2.68
- Min
- 0.73
TMO’s P/S Ratio of 4.33 aligns with the market consensus for the Life Sciences Tools & Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
VTRS
0.88
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
In the lower quartile for the Pharmaceuticals industry, VTRS’s P/S Ratio of 0.88 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.
Price-to-Book Ratio (MRQ)
TMO
3.03
Life Sciences Tools & Services Industry
- Max
- 7.99
- Q3
- 4.69
- Median
- 3.30
- Q1
- 1.88
- Min
- 1.02
TMO’s P/B Ratio of 3.03 is within the conventional range for the Life Sciences Tools & Services industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
VTRS
0.67
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
VTRS’s P/B Ratio of 0.67 is in the lower quartile for the Pharmaceuticals industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.
Valuation at a Glance
| Symbol | TMO | VTRS |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 28.41 | -- |
| Price-to-Sales Ratio (TTM) | 4.33 | 0.88 |
| Price-to-Book Ratio (MRQ) | 3.03 | 0.67 |
| Price-to-Free Cash Flow Ratio (TTM) | 30.32 | 7.29 |